

ASX ANNOUNCEMENT

JAPANESE PATENT GRANTED FOR USE OF MIDKINE FOR HAIR GROWTH

- **Patent for use of midkine to prevent and treat hair loss and to promote and enhance hair growth granted**
- **Comprehensive protection over midkine and related protein pleiotrophin with long patent life (to 2031)**
- **Major boost to Cellmid's hair growth asset portfolio**

SYDNEY, 24 November 2015: Cellmid Limited (ASX: CDY) has received official notice from the Japanese Patent Office that Cellmid's patent application 2012-554162 entitled *Method of treatment or prevention of hair loss or for the enhancement of hair growth* has been granted.

This patent protects the use of midkine and the closely related protein pleiotrophin for use as hair loss and/or hair growth treatments. The granted claims cover topical formulations of all kinds, including shampoos, conditioners, creams and lotions with protection until 2031.

This patent is the third member of the extensive midkine patent family for hair growth to be accepted, following the granting of the UK and Australian patents. Other patents are filed or are under examination in the USA, Europe, China, Hong Kong and Korea.

This patent family adds to the already considerable intellectual property assets of Cellmid's wholly owned anti-aging hair growth subsidiary, Advangen Limited, which include patent protection and extensive know-how around its FGF5 inhibiting technologies, cell based assays, formulations and brands.

Advangen's products are on sale in Australia and Japan, closely followed by Taiwan and China. The Company is actively pursuing other market opportunities including USA, Europe and other parts of Asia. Advangen's business is underpinned by an innovative and scientifically validated product pipeline including novel FGF5 inhibitors as well as midkine-based products.

Anti-aging is one of the fastest growing segments of the \$90 billion annual hair care market. Hair loss, caused by age and androgenic factors, is a condition that effects around 30% of women and 50% of men over 40. There is a dearth of effective products that prevent hair loss and regenerate resting hair follicles. Cellmid, through its wholly owned subsidiary Advangen, has a range of hair growth and anti-aging hair care technologies and is well positioned to take a leading role in this rapidly growing market segment.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830



@mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead drug candidates in multiple disease indications. The Company is developing innovative novel therapies and diagnostic tests for cancer and inflammatory diseases as well as OTC treatments for hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel target midkine and midkine antagonists globally. The Company's most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer. For further information please see www.cellmid.com.au.

Advangen Limited and hair growth products

Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of anti-aging hair care products. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, China and Taiwan. Concurrently, Advangen has been studying midkine, a growth factor, in hair loss models utilising its anti-apoptotic effects. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes.

Midkine (MK)

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is highly anti-apoptotic protecting cells from dying. It is this mechanism of action that is thought to be responsible for midkine's ability to regenerate hair growth in various models of the condition.